Latest news with #DTIGN
Business Times
16-05-2025
- Business
- Business Times
Revolutionising drug discovery with AI in South-east Asia
Founder's experience The genesis of was a personal one, sparked by the founder's experience with the limitations of conventional medicine and the potential of traditional remedies. This personal connection fuelled the drive to develop a more efficient and effective approach to drug discovery. Its proprietary platform, DTIGN, launched in Q4 2024, utilises graph neural networks and molecular docking models to significantly improve drug-target interaction predictions. This technology has already outperformed second-best methods by 25 per cent, as recognised by IEEE Magazine. SEE ALSO Sengkang General Hospital leads the way in automating sterile supply management GET BT IN YOUR INBOX DAILY Start and end each day with the latest news stories and analyses delivered straight to your inbox. Sign Up VIEW ALL DTIGN's unique approach integrates signalling pathways, reaction environments, pharmacokinetics and species-specific variations in bioactivity modelling. Unlike typical AI-driven drug discovery, which often focuses on synthetic compounds, DTIGN prioritises plant-derived compounds from South-east Asia, unlocking unique therapeutic mechanisms. In addition to revolutionising pharmaceutical drug discovery, DTIGN's capabilities extend to other industries. The platform is being applied to the beauty sector, where plant-based bioactives are used for anti-aging, skin health and rejuvenation products. DTIGN is also supporting innovation in animal health, including the development of solutions for zoonotic diseases. This cross-industry versatility highlights the broad impact of technology and its potential to transform multiple sectors reliant on bioactive compounds. The company's AI capabilities offer cost-effective solutions, accelerated molecule discovery and a faster time to market. also leverages a vast collection of billions of natural and synthetic compounds, enhancing its drug discovery process. DTIGN's efficiency is underscored by its use of Nvidia H100 GPUs, which have dramatically reduced model training (from 80 to 10 hours) and docking (from 70 to eight hours) runtimes. AI models like AlphaFold, DiffDock and MolMIM further enhance the platform's predictive capabilities. has already secured its first revenue of US$200,000 (S$261,110) from Delightex (Japan Tobacco Inc) and has established strategic partnerships with HPE, Nvidia and Equinix for AI infrastructure and go-to-market strategies. The company has also been accepted to present at Nvidia GTC 2025 and has been selected for the Nvidia Ignition Program and JLABS. Ethical considerations and sustainability are central to operations. The company operates a 6,000 square foot research lab at Nanyang Technological University, ensuring transparency, accountability and patient safety. It focuses on developing affordable treatments for complex diseases, as well as promoting healthcare equity and accessibility. also supports sustainable harvesting and conservation efforts of plant-derived compounds and integrates energy-efficient AI computing. The impact of technology is significant. The company has reduced novel compound discovery timelines from 12 to 15 years to two to five years, improved bioactivity prediction accuracy by 44.83 per cent, and achieved a 64x higher hit-rate efficiency compared to traditional methods. Projected revenue growth from US$2 million to US$10 million between 2025 and 2030 demonstrates the platform's commercial viability. Beyond quantitative impact, aims to enhance the sustainable quality of life by democratising access to affordable, effective treatments and supporting biodiversity conservation. Globally iconic innovation Its user-centric design and international recognition, including its feature in IEEE Magazine, position DTIGN as a globally iconic innovation. journey is more than a story of technological triumph – it's a testament to what is possible when empathy, science and sustainability converge.
Associated Press
10-05-2025
- Business
- Associated Press
Nanyang Biologics and Precisya Global Inc Announce Strategic Collaboration to Validate Natural Compounds Against Genetic Disease Markers
SINGAPORE & WILMINGTON, Del.--(BUSINESS WIRE)--May 10, 2025-- Nanyang Biologics (NYB) and Precisya Global Inc (PGI) announce a strategic collaboration to leverage our technologies in validating potential therapeutic benefits of natural compounds against genetically identified risk factors and predispositions for chronic diseases. The partnership combines PGI's genomic big data analytics with NYB's natural compound libraries and AI capabilities. The collaboration will leverage DTIGN (Drug-Target Interaction Graph Neural Network), NYB's proprietary AI model that has demonstrated a 27.03% improvement in prediction accuracy over leading methods. DTIGN significantly enhances the identification of active compounds and shortens early-stage discovery timelines. This technology will be used to screen compounds as NYB continues to build one of the world's largest natural compound libraries, unlocking novel therapeutic opportunities with exceptional precision and speed. As a key contributor to this strategic partnership, Precisya Global Inc will utilize advanced genomic data analysis platforms and specialized genetic knowledge from 22+ Million Scientific Publications to identify disease-relevant biomarkers. The company will provide secure access to anonymized patient genomic data in compliance with privacy regulations, while offering expert bioinformatic analysis of correlations between natural compound responses and genetic variants. This joint initiative bridges the gap between genomic analysis and natural compound research, aiming to accelerate the discovery of nature-based treatments for genetic diseases through AI-driven matching and rigorous validation processes. This enables personalized nature-based treatments for individuals with genetic health conditions, offering better outcomes, fewer side effects, and more affordable options. 'This collaboration represents a significant advancement in precision medicine,' said Roland Ong, Founder and Chairman of Nanyang Biologics. 'By combining our natural compound expertise and DTIGN technology with PGI's genomic capabilities, we aim to develop more targeted and effective treatments while significantly reducing the time and cost typically associated with drug discovery.' The partnership includes comprehensive validation through in vitro and in vivo assays, supported by joint biobanks and patient samples. This integrated approach ensures robust validation of potential therapeutic compounds while maintaining high scientific standards. About Precisya Global Inc: Precisya Global Inc (PGI) is a leading deep health tech company with its genomic big data and unique algorithms that maps the genetic interference pattern across the whole body metabolic pathway, identifying the causative and associative factors of chronic disease expressions Through PGI state-of-the-art technology platform and comprehensive genomic database, PGI delivers precise, data-driven insights that enable personalized healthcare solutions and accelerate plant based compounds drug development processes. About Nanyang Biologics Nanyang Biologics (NYB) is a biotech company using AI and biological data to understand drug-target interactions in disease pathways. Through its AI platform and compound libraries, NYB identifies promising therapeutic molecules and optimizes them for effectiveness. Using advanced machine learning techniques, NYB accelerates the discovery of next-generation treatments for cancer and chronic diseases. View source version on CONTACT: For media inquiries: Quynh Nguyen Senior AI Partnership Manager Nanyang Biologics [email protected] KEYWORD: NORTH AMERICA UNITED STATES ASIA PACIFIC SINGAPORE SOUTHEAST ASIA DELAWARE INDUSTRY KEYWORD: TECHNOLOGY GENETICS HEALTH TECHNOLOGY PROFESSIONAL SERVICES BIOMETRICS BIOTECHNOLOGY DATA ANALYTICS PHARMACEUTICAL HEALTH ARTIFICIAL INTELLIGENCE SOURCE: Nanyang Biologics Copyright Business Wire 2025. PUB: 05/10/2025 08:09 AM/DISC: 05/10/2025 08:09 AM
Business Wire
10-05-2025
- Business
- Business Wire
Nanyang Biologics and Precisya Global Inc Announce Strategic Collaboration to Validate Natural Compounds Against Genetic Disease Markers
SINGAPORE & WILMINGTON, Del.--(BUSINESS WIRE)--Nanyang Biologics (NYB) and Precisya Global Inc (PGI) announce a strategic collaboration to leverage our technologies in validating potential therapeutic benefits of natural compounds against genetically identified risk factors and predispositions for chronic diseases. The partnership combines PGI's genomic big data analytics with NYB's natural compound libraries and AI capabilities. The collaboration will leverage DTIGN (Drug-Target Interaction Graph Neural Network), NYB's proprietary AI model that has demonstrated a 27.03% improvement in prediction accuracy over leading methods. DTIGN significantly enhances the identification of active compounds and shortens early-stage discovery timelines. This technology will be used to screen compounds as NYB continues to build one of the world's largest natural compound libraries, unlocking novel therapeutic opportunities with exceptional precision and speed. As a key contributor to this strategic partnership, Precisya Global Inc will utilize advanced genomic data analysis platforms and specialized genetic knowledge from 22+ Million Scientific Publications to identify disease-relevant biomarkers. The company will provide secure access to anonymized patient genomic data in compliance with privacy regulations, while offering expert bioinformatic analysis of correlations between natural compound responses and genetic variants. This joint initiative bridges the gap between genomic analysis and natural compound research, aiming to accelerate the discovery of nature-based treatments for genetic diseases through AI-driven matching and rigorous validation processes. This enables personalized nature-based treatments for individuals with genetic health conditions, offering better outcomes, fewer side effects, and more affordable options. "This collaboration represents a significant advancement in precision medicine," said Roland Ong, Founder and Chairman of Nanyang Biologics. "By combining our natural compound expertise and DTIGN technology with PGI's genomic capabilities, we aim to develop more targeted and effective treatments while significantly reducing the time and cost typically associated with drug discovery." The partnership includes comprehensive validation through in vitro and in vivo assays, supported by joint biobanks and patient samples. This integrated approach ensures robust validation of potential therapeutic compounds while maintaining high scientific standards. About Precisya Global Inc: Precisya Global Inc (PGI) is a leading deep health tech company with its genomic big data and unique algorithms that maps the genetic interference pattern across the whole body metabolic pathway, identifying the causative and associative factors of chronic disease expressions Through PGI state-of-the-art technology platform and comprehensive genomic database, PGI delivers precise, data-driven insights that enable personalized healthcare solutions and accelerate plant based compounds drug development processes. About Nanyang Biologics Nanyang Biologics (NYB) is a biotech company using AI and biological data to understand drug-target interactions in disease pathways. Through its AI platform and compound libraries, NYB identifies promising therapeutic molecules and optimizes them for effectiveness. Using advanced machine learning techniques, NYB accelerates the discovery of next-generation treatments for cancer and chronic diseases.
